OpenURL Connection Search

Select item for more details and to access through your institution.

Anti-EGFR monoclonal antibodies which act as EGF, TGFα, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
Published in:
International Journal of Cancer, 1998, v. 75, n. 2, p. 310, doi. 10.1002/(SICI)1097-0215(19980119)75:2<310::AID-IJC22>3.0.CO;2-F
By:
- Modjtahedi, Helmout;
- Komurasaki, Toshi;
- Toyoda, Hitoshi;
- Dean, Christopher
Publication type:
Article
Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer.
Published in:
Cancer Immunology, Immunotherapy, 2024, v. 73, n. 2, p. 1, doi. 10.1007/s00262-023-03608-y
By:
- Otsuka, Koji;
- Isobe, Junya;
- Asai, Yoshiyuki;
- Nakano, Tomohisa;
- Hattori, Kouya;
- Ariyoshi, Tomotake;
- Yamashita, Takeshi;
- Motegi, Kentaro;
- Saito, Akira;
- Kohmoto, Masahiro;
- Hosonuma, Masahiro;
- Kuramasu, Atsuo;
- Baba, Yuta;
- Murayama, Masakazu;
- Narikawa, Yoichiro;
- Toyoda, Hitoshi;
- Funayama, Eiji;
- Tajima, Kohei;
- Shida, Midori;
- Hirasawa, Yuya
Publication type:
Article
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.
Published in:
Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-59677-1
By:
- Murayama, Masakazu;
- Hosonuma, Masahiro;
- Kuramasu, Atsuo;
- Kobayashi, Sei;
- Sasaki, Akiko;
- Baba, Yuta;
- Narikawa, Yoichiro;
- Toyoda, Hitoshi;
- Isobe, Junya;
- Funayama, Eiji;
- Tajima, Kohei;
- Sasaki, Aya;
- Maruyama, Yuki;
- Yamazaki, Yoshitaka;
- Shida, Midori;
- Hamada, Kazuyuki;
- Hirasawa, Yuya;
- Tsurui, Toshiaki;
- Ariizumi, Hirotsugu;
- Ishiguro, Tomoyuki
Publication type:
Article
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.
Published in:
Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1164724
By:
- Kazuyuki Hamada;
- Junya Isobe;
- Kouya Hattori;
- Masahiro Hosonuma;
- Yuta Baba;
- Masakazu Murayama;
- Yoichiro Narikawa;
- Hitoshi Toyoda;
- Eiji Funayama;
- Kohei Tajima;
- Midori Shida;
- Yuya Hirasawa;
- Toshiaki Tsurui;
- Hirotsugu Ariizumi;
- Tomoyuki Ishiguro;
- Risako Suzuki;
- Ryotaro Ohkuma;
- Yutaro Kubota;
- Takehiko Sambe;
- Mayumi Tsuji
Publication type:
Article
Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tryosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
Published in:
Oncogene, 1997, v. 15, n. 23, p. 2841, doi. 10.1038/sj.onc.1201458
By:
- Komurasaki, Toshi;
- Toyoda, Hitoshi;
- Uchida, Daisuke;
- Morimoto, Shigeo
Publication type:
Article
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Published in:
Cancer Science, 2024, v. 115, n. 3, p. 752, doi. 10.1111/cas.16061
By:
- Hosonuma, Masahiro;
- Hirasawa, Yuya;
- Kuramasu, Atsuo;
- Murayama, Masakazu;
- Narikawa, Yoichiro;
- Toyoda, Hitoshi;
- Baba, Yuta;
- Isobe, Junya;
- Funayama, Eiji;
- Tajima, Kohei;
- Shida, Midori;
- Hamada, Kazuyuki;
- Tsurui, Toshiaki;
- Ariizumi, Hirotsugu;
- Ishiguro, Tomoyuki;
- Suzuki, Risako;
- Ohkuma, Ryotaro;
- Kubota, Yutaro;
- Horiike, Atsushi;
- Sambe, Takehiko
Publication type:
Article

Found: 6

Anti-EGFR monoclonal antibodies which act as EGF, TGFα, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.

Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer.

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.

Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tryosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.

Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.